Martin, PJ, Counts, GW Jr, Appelbaum, FR, et al. Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation. J Clin Oncol. 2010; 28: 1011–6.Google Scholar

Bhatia, S, Francisco, L, Carter, A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007; 110: 3784–92.Google Scholar

Cooke, KR, Yanik, GA. Lung injury following hematopoietic cell transplantation. In: Appelbaum, FR, Forman, SJ, Negrin, SJ, Blume, KG, eds. Thomas’ Hematopoietic Cell Transplantation , 4th edn. Malden, MA, Blackwell Publishing, 2009, pp 1456–71.Google Scholar

Panoskaltsis-Mortari, A, Griese, M, Madtes, DK, et al. An official American Thoracic Society research statement: noninfectious lung injury after hematopoietic stem cell transplantation: idiopathic pneumonia syndrome. Am J Respir Crit Care Med. 2011; 183: 1262–79.CrossRefGoogle ScholarPubMed

Carreras, E. Early complications after HSCT. In: Apperley, J, Carreras, E, Gluckman, E, Mazzi, T, eds. EBMT Handbook of Hematopoietic Stem Cell Transplantation. Genoa, Italy, Forum Service Editore, 2012, pp 177–94.Google Scholar

Lucena, CM, Torres, A, Rovira, M, et al. Pulmonary complications in hematopoietic SCT: a prospective study. Bone Marrow Transplant. 2014 Jul 21. doi:10.1038/bmt.2014.151. [Epub ahead of print] PubMed PMID: 25046219.Google Scholar

Socié, G, Salooja, N, Cohen, A, et al Nonmalignant late effects after allogeneic stem cell transplantation. Blood. 2003; 101: 3373–85.CrossRefGoogle ScholarPubMed

Flowers, MED, Deeg, HJ. Delayed non-malignant complications after hematopoietic cell transplantation. In: Appelbaum, FR, Forman, SJ, Negrin, SJ, Blume, KG, eds. Thomas’ Hematopoietic Cell Transplantation , 4th edn. Malden, MA, Blackwell Publishing, 2009, pp 1620–36.Google Scholar

Yanik, GA, Horowitz, MM, Weisdorf, DJ, et al. Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: Enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. Biol Blood Marrow Transplant. 2014; 20: 858–64.Google Scholar

Afessa, B, Tefferi, A, Litzow, MR, Krowka, MJ, Wylam, ME, Peters, SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002; 166: 641–5.Google ScholarPubMed

Majhail, NS, Parks, K, Defor, TE, Weisdorf, DJ. Diffuse alveolar hemorrhage and infection-associated alveolar hemorrhage following hematopoietic stem cell transplantation: related and high-risk clinical syndromes. Biol Blood Marrow Transplant. 2006; 12:1038–46.Google ScholarPubMed

Elinoff, JM, Bagci, U, Moriyama, B, et al. Recombinant human factor VIIa for alveolar hemorrhage following allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20: 969–78.CrossRefGoogle ScholarPubMed

Carreras, E, Diaz-Ricart M, . The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 201; 46: 1495–502.Google Scholar

Paczesny, S, Diaz-Ricart, M, Carreras, E, Cooke, KR. Translational research efforts in biomarkers and biology of early transplant-related complications. Biol Blood Marrow Transplant. 2011; 17(Suppl): S101–8.CrossRefGoogle ScholarPubMed

Penack, O, Socié, G, van den Brink, MR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood. 2011; 117: 4181–9.CrossRefGoogle ScholarPubMed

Carreras, E, Fernández-Avilés, F, Silva, L, et al. Engraftment syndrome alters auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant. 2010; 45: 1417–22.CrossRefGoogle Scholar

Maiolino, A, Biasoli, I, Lima, J, et al. Engraftment syndrome following autologous hematopoietic stem cell transplantation: definition of diagnostic criteria. Bone Marrow Transplant. 2003; 31: 393–7.CrossRefGoogle ScholarPubMed

Speizer, TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant. 2001; 27: 893–8.Google Scholar

Cornell, RF, Hari, P, Zhang, MJ, et al. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the risk of engraftment syndrome after autologous peripheral blood stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2013; 19: 1368–73.CrossRefGoogle ScholarPubMed

Gorak, E, Geller, N, Srinivasan, R, et al. Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival. Biol Blood Marrow Transplant. 2005; 11: 542–50.Google Scholar

Hong, KT, Kang, HJ, Kim, NH, et al. Peri-engraftment syndrome in allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013; 48: 523–8.CrossRefGoogle ScholarPubMed

Chang, L, Frame, D, Braun, T, et al. Engraftment syndrome after allogeneic hematopoietic cell transplantation predicts poor outcomes. Biol Blood Marrow Transplant. 2014; 20: 1407–17.CrossRefGoogle ScholarPubMed

Cho, BS, Yahng, SA, Lee, SE, et al. Validation of recently proposed consensus criteria for thrombotic microangiopathy after allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010; 90: 918–26.Google Scholar

Ruutu, T, Barosi, G, Benjamin, RJ, et al. Diagnostic criteria for hematopoietic stem cell transplant-associated microangiopathy: results of a consensus process by an International Working Group. Haematologica. 2007; 92: 95–100.Google Scholar

Ho, VT, Cutler, C, Carter, S, et al. Blood and Marrow Transplant Clinical Trials Network Toxicity Committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005; 11: 571–5.CrossRefGoogle ScholarPubMed

Carmona, A, Díaz-Ricart, M, Palomo, M, et al. Distinct deleterious effects of cyclosporine and tacrolimus and combined tacrolimus-sirolimus on endothelial cells: protective effect of defibrotide. Biol Blood Marrow Transplant. 2013; 19: 1439–45.Google Scholar

Laskin, BL, Goebel, J, Davies, SM, Jodele, S. Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplant associated-thrombotic microangiopathy. Blood. 2011; 118: 1452–62.Google Scholar

Daly, AS, Xenocostas, A, Lipton, JH. Transplantation-associated thrombotic microangiopathy: twenty-two years later. Bone Marrow Transplant. 2002; 30: 709–15.Google Scholar

Tichelli, A, Bucher, C, Rovó, A, et al., Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. Blood. 2007; 110: 3463–71.Google Scholar

Tichelli, A, Passweg, J, Wójcik, D, et al. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the EBMT. Haematologica. 2008; 93: 1203–10.Google Scholar

Chow, EJ, Wong, K, Lee, SJ, et al. Late cardiovascular complications after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2014; 20: 794–800.Google Scholar

Baker, KS, Chow, E, Steinberger, J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47: 619–25.CrossRefGoogle ScholarPubMed

Baker, KS, Ness, KK, Steinberger, J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007; 109: 1765–72.Google Scholar

Armenian, SH, Sun, CL, Vase, T, et al., Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012; 120: 4505–12.Google Scholar

Majhail, NS, Rizzo, JD, Lee, SJ, et al. Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2012; 18: 348–71.Google Scholar

McDonald, GB, Sharma, P, Matthews, DE, Shulman, HM, Thomas, ED. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors. Hepatology 1984; 4: 116–22.Google Scholar

Jones, RJ, Lee, KS, Beschorner, WE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778–83.CrossRefGoogle ScholarPubMed

Carreras, E, Grañena, A, Navasa, M, et al. On the reliability of clinical criteria for the diagnosis of hepatic veno-occlusive disease. Ann Hematol. 1993; 66: 77–80.Google Scholar

Corbacioglu, S, Cesaro, S, Faraci, M, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012; 379: 1301–9.Google Scholar

Lee, JL, Gooley, T, Bensinger, W, Schiffman, K, McDonald, GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant. 1999; 5: 306–15.CrossRefGoogle ScholarPubMed

Carreras, E, Fernández-Avilés, F, Silva, L, et al. Engraftment syndrome alter auto-SCT: analysis of diagnostic criteria and risk factors in a large series from a single center. Bone Marrow Transplant. 2010; 45: 1417–22.Google Scholar

Strasser, SI, McDonald, GB. Gastrointestinal and hepatic complications. In: Appelbaum, FR, Forman, SJ, Negrin, SJ, Blume, KG, eds. Thomas’ Hematopoietic Cell Transplantation , 4th edn. Malden, MA, Blackwell Publishing, 2009, pp 1434–55.Google Scholar

Coppell, JA, Richardson, PG, Soiffer, R, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010; 16: 157–68.Google Scholar

Carreras, E, Díaz-Beyá, M, Rosiñol, L, et al. The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. Biol Blood Marrow Transplant. 2011; 17: 1713–20.CrossRefGoogle ScholarPubMed

Carreras, E, Bertz, H, Arcese, W, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the EBMT. Blood. 1998; 92: 3599–604.Google ScholarPubMed

Soiffer, RJ, Dear, K, Rabinowe, SN, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991; 52: 1014–9.Google Scholar

Moscardó, F, Urbano-Ispizua, A, Sanz, GF, et al. Positive selection for CD34+ reduces the incidence and severity of veno-occlusive disease of the liver after HLA-identical sibling allogeneic peripheral blood stem cell transplantation. Exp Hematol. 2003; 31: 545–50.Google Scholar

Vallejo, C, Batlle, M, Vazquez, L, et al. Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation. Haematologica. 2014; Jul 4. [Epub ahead of print] PubMed PMID: 24997153.Google Scholar

Hägglund, H, Remberger, M, Klaesson, S, Lönnqvist, B, Ljungman, P, Ringden, O. Norethisterone treatment, a major risk factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood. 1998; 92: 4568–72.CrossRefGoogle Scholar

Daly, A, Savoie, ML, Geddes, M, et al. Fludarabine, busulfan, antithymocyte globulin, and total body irradiation for pretransplantation conditioning in acute lymphoblastic leukemia: excellent outcomes in all but older patients with comorbidities. Biol Blood Marrow Transplant. 2012; 18: 1921–6.Google Scholar

Cantoni, N, Gerull, S, Heim, D, et al. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011; 46: 344–9.CrossRefGoogle ScholarPubMed

Deeg, HJ, Shulman, HM, Schmidt, E, Yee, GC, Thomas, ED, Storb, R. Marrow graft rejection and veno-occlusive disease of the liver in patients with aplastic anemia conditioned with cyclophosphamide and cyclosporine. Transplantation. 1986; 42: 497–501.Google Scholar

Dignan, FL, Wynn, RF, Hadzic, N, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013; 163: 444–57.CrossRefGoogle ScholarPubMed

Ruutu, T, Juvonen, E, Remberger, M, et al. Improved survival with ursodeoxycholic acid prophylaxis in allogeneic stem cell transplantation: long-term follow-up of a randomized study. Biol Blood Marrow Transplant. 2014; 20: 135–8.Google Scholar

Carreras, E. How I treat sinusoidal obstruction syndrome after hematopoietic cell transplantation. Br J Haematol. 2015; 168: 481–91.Google Scholar

Carreras, E, Grañena, A, Navasa, M, et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant. 1993; 11: 21–6.Google Scholar

Hingorani, S. Kidney and bladder complications of hematopoietic cell transplantation. In: Appelbaum, FR, Forman, SJ, Negrin, SJ, Blume, KG, eds. Thomas’ Hematopoietic Cell Transplantation; 4th edn. Malden, MA, Blackwell Publishing, 2009, pp 1473–86.Google Scholar

Silva, L, Patah, PA, Saliba, RM, et al. Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type. Haematologica. 2010; 95: 1183–90.Google Scholar

Raiola, AM, Dominietto, A, Ghiso, A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013; 19: 117–22.Google Scholar

Shepherd, JD, Pringle, LE, Barnett, MJ, Klingemann, HG, Reece, DE, Phillips, GL. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol. 1991; 9: 2016–20.Google Scholar

Giné, E, Rovira, M, Real, I, et al. Successful treatment of severe hemorrhagic cystitis after hemopoietic cell transplantation by selective embolization of the vesical arteries. Bone Marrow Transplant. 2003; 31: 923–5.Google Scholar

Tichelli, A, Socié, G. Late effects in patients treated with HSCT. In: Apperley, J, Carreras, E, Gluckman, E, Mazzi, T eds. EBMT Handbook of Hematopoietic Stem Cell Transplantation. Genoa, Italy, Forum Service Editore, 2012, pp 249–67.Google Scholar

Choi, M, Sun, CL, Kurian, S, et al. Incidence and predictors of delayed chronic kidney disease in long-term survivors of hematopoietic cell transplantation. Cancer. 2008; 113: 1580–7.Google Scholar

Kandeel, FR. Endocrine complications following hematopoietic cell transplantation. In: Appelbaum, FR, Forman, SJ, Negrin, SJ, Blume, KG, eds. Thomas’ Hematopoietic Cell Transplantation; 4th edn. Malden, MA, Blackwell Publishing, 2009, pp 1487–522.Google Scholar

Sanders, JE, Hoffmeister, PA, Woolfrey, AE, et al. Thyroid function following hematopoietic cell transplantation in children: 30 years’ experience. Blood. 2009; 113: 306–8.CrossRefGoogle ScholarPubMed

Sanders, JE. Growth and development after hematopoietic cell transplantation. In: Appelbaum, FR, Forman, SJ, Negrin, SJ, Blume, KG, eds, Thomas’ Hematopoietic Cell Transplantation; 4th edn. Malden, MA, Blackwell Publishing, 2009, pp 1608–16.Google Scholar

Loren, AW, Chow, E, Jacobsohn, DA, et al. Pregnancy after hematopoietic cell transplantation: a report from the late effects working committee of the Center for International Blood and Marrow Transplant Research (CIBMTR). Biol Blood Marrow Transplant. 2011; 17: 157–66.Google Scholar

Joshi, S, Savani, BN, Chow, EJ, et al. Clinical guide to fertility preservation in hematopoietic cell transplant recipients. Bone Marrow Transplant. 2014; 49: 477–84.Google Scholar

Kraus, PD, Wolff, D, Grauer, O, et al. Muscle cramps and neuropathies in patients with allogeneic hematopoietic stem cell transplantation and graft-versus-host disease. PLoS One. 2012; 7: e44922.Google Scholar

Bosch, M., and Storek, J.. Immune reconstitution after hematopoietic cell transplantation. Curr Opin Hematol 2012; 19:324–35.CrossRefGoogle ScholarPubMed

Savani, B. N., Adams, S., Uribe, M., et al. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia. Leukemia 2007; 21:2145–52.CrossRefGoogle Scholar

Le Blanc, K., Schaffer, M., Hägglund, H., et al. Lymphocyte recovery is a major determinant of outcome after matched unrelated myeloablative transplantation for myelogenous malignancies. Biol Blood Marrow Transplant 2009; 15:1108–15.Google Scholar

Michelis, F. V., Loach, D., Uhm, J., et al. Early lymphocyte recovery at 28 d post-transplant is predictive of reduced risk of relapse in patients with acute myeloid leukemia transplanted with peripheral blood stem cell grafts. Eur J Haematol 2014; 93(4):273–80. .Google Scholar

Burke, M. J., Janardan, S. K., Brunstein, C., et al. Early lymphocyte recovery and outcomes after umbilical cord blood transplantation (UCBT) for hematologic malignancies. Biol Blood Marrow Transplant 2011; 17:831–40.Google Scholar

Komanduri, K. V., de Lima, M., McMannis, J., et al. Delayed immune reconstitution after cord blood transplantation is characterized by impaired thymopoiesis and late memory T-cell skewing. Blood 2007; 110:4543–51.Google Scholar

Satpathy, A. T., Albring, J. C., and Murphy, K. M.. Re(de)fining the dendritic cell lineage. Nat Immunol 2012; 13:1145–54.Google Scholar

Ruggeri, L., Urbani, E., Perruccio, K., et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097–100.CrossRefGoogle ScholarPubMed

Ruggeri, L., Burchielli, E., Capanni M, M., et al. NK cell alloreactivity and allogeneic hematopoietic stem cell transplantation. Blood Cells Mol Dis 2008; 40:84–90.Google Scholar

Chang, Y. J., and Huang, X. J.. Effects of the NK cell recovery on outcomes of unmanipulated haploidentical blood and marrow transplantation for patients with hematologic malignancies. Biol Blood Marrow Transplant 2008; 14:323–34.Google Scholar

Della Chiesa, M., Muccio, L., Bertaina, A., et al. Impact of HCMV infection on NK cell development and function after HCT. Front Immunol 2013; 4:458.Google Scholar

Gudiol, C., Arnan, M., Sánchez-Ortega, I., et al. Etiology, clinical features and outcomes of pre-engraftment and post-engraftment bloodstream infection in hematopoietic SCT recipients. Bone Marrow Transplant 2014; 49:824−30.Google Scholar

Mackall, C., Gress, R., Peggs, K., et al; Center for International Blood and Marrow Transplant Research (CIBMTR); National Marrow Donor Program (NMDP); European Blood and Marrow Transplant Group (EBMT); American Society of Blood and Marrow Transplantation (ASBMT); Canadian Blood and Marrow Transplant Group (CBMTG); Infectious Disease Society of America (IDSA); Society for Healthcare Epidemiology of America (SHEA); Association of Medical Microbiology and Infectious Diseases Canada (AMMI); Centers for Disease Control and Prevention (CDC). Background to hematopoietic cell transplantation, including post transplant immune recovery. Bone Marrow Transplant 2009; 44:457–62.Google Scholar

Fozza, C.. T-cell receptor repertoire usage in hematologic malignancies. Crit Rev Oncol Hematol 2013; 86:201–11.Google Scholar

Kim, D. H., Won, D. I., Lee, N. Y., et al. Rapid helper T-cell recovery above 200 x 10 6/l at 3 months correlates to successful transplant outcomes after allogeneic stem cell transplantation. Bone Marrow Transplant 2006; 37:1119–28.Google Scholar

Fedele, R., Garreffa, C., Messina, G., et al. The impact of early CD4+ lymphocyte recovery on the outcome of patients who undergo allogeneic bone marrow or peripheral blood stem cell transplantation. Blood Transfus 2012; 10:174–80.Google Scholar

Six A, A., Chaara, W., Magadan, S., et al. The past, present, and future of immune repertoire biology − the rise of next-generation repertoire analysis. Front Immunol 2013; 4:413.Google ScholarPubMed

Krenger, W., and Holländer, G. A.. Thymic T-cell development in allogeneic stem cell transplantation. Blood 2011; 117:6758–76.Google Scholar

Ringhoffer, S., Döhner, H., Bunjes, D., et al. T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naive T cells. Haematologica 2013; 98:1600–8.Google Scholar

Toubert, A., Douay, C., and Clave, E.. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens 2012; 79:83–9.Google Scholar

Rueff, J., Heim, D., Passweg, J., et al. Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. Biol Blood Marrow Transplant 2014; 20:869–9.Google Scholar

Muraro, P., Malhotra, S., Howell, M., et al. T cell repertoire following autologous stem cell transplantation for multiple sclerosis. J Clin Invest 2014; 124:1168–72.Google Scholar

Ciurea, S. O., Saliba, R. M., Bayraktar, U. D., et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012; 18:1835–44.Google Scholar

Chevallier, P., Illiaquer, M., Esbelin, J., et al. Characterization of various blood and graft sources: a prospective series. Transfusion 2013; 53:2020–6.Google Scholar

Escalón, M. P.. Cord blood transplantation: evolving strategies to improve engraftment and immune reconstitution. Curr Opin Oncol 2010; 22:122–9.Google Scholar

Gärtner, F., Finke, J., and Bertz, H.. Lowering the alemtuzumab dose in reduced intensity conditioning allogeneic hematopoietic cell transplantation is associated with a favorable early intense natural killer cell recovery. Cytotherapy 2013; 15:1237–44.Google Scholar

Streitz, M., Kapinsky, M., Reed, M., et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res 2013; 2:17.Google Scholar